Use of well-defined HIV-derived epitopes to evaluate CD4+ and CD8+ T cell responses in patients with chronic HIV-1 infection treated with HAART

AIDS Research and Human Retroviruses

Volumn 20, Issue 8, 2004, Pages 827-835

  Daniel, Nathalie ^a,b   Charmeteau, Bénédicte ^a   Grabar, Sophie ^b   Pialoux, Gilles ^c   Salmon, Dominique ^b   Bonilla, Nelly ^a   Dupuis, Marion ^a   Troadec, Christelle ^a   Rozenbaum, Willy ^c   Gahéry Ségard, Hanne ^a   Guillet, Jean Gérard ^a   Andrieu, Muriel ^a  

^a INSTITUT COCHIN   (France)

^b Cochin Hospital ^*  (France)

^c HÔPITAL TENON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CD8 ANTIGEN; EPITOPE; GAMMA INTERFERON;

ANALYTIC METHOD; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG RESPONSE; ENZYME LINKED IMMUNOSPOT ASSAY; EX VIVO STUDY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HLA SYSTEM; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME; VIRUS LOAD;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; EPITOPES; HIV INFECTIONS; HIV-1; HUMANS; LYMPHOCYTE COUNT;

EID: 4344675190     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/0889222041725145     Document Type: Article

References (32)

1. Autran B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R, Katlama C, Debre P, and Leibowitch J: Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997;277:112-116.
2. Li T, Tubiana R, Katlama C, Calvez V, Ait MH, and Autran B: Long-lasting recovery in CD4 T cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet 1998;351:1682-1686.
3. Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, Smith K, Lisziewicz J, Lori F, Flexner C, Quinn TC, Chaisson RE, Rosenberg E, Walker B, Gange S, Gallant J, and Siliciano RF: Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999;5:512-517.
4. Zhang L, Ramratnam B, Tenner-Racz K, He Y, Vesanen M, Lewin S, Talal A, Racz P, Perelson AS, Korber BT, Markowitz M, and Ho DD: Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med 1999;340:1605-1613.
5. Appay V, Hansasuta P, Sutton J, Schrier RD, Wong JK, Furtado M, Havlir DV, Wolinsky SM, McMichael AJ, Richman DD, Rowland-Jones SL, and Spina CA: Persistent HIV-1-specific cellular responses despite prolonged therapeutic viral suppression. AIDS 2002;16:161-170.
6. Kalams S, Goulder P, Shea A, Jones N, Trocha A, Ogg G, and Walker B: Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy. J Virol 1999;73:6721-6728.
7. Rinaldo CR, Jr., Huang XL, Fan Z, Margolick JB, Borowski L, Hoji A, Kalinyak C, McMahon DK, Riddler SA, Hildebrand WH, Day RB, and Mellors JW: Anti-human immunodeficiency virus type 1 (HIV-1) CD8(+) T-lymphocyte reactivity during combination antiretroviral therapy in HIV-1-infected patients with advanced immunodeficiency. J Virol 2000;74:4127-4138.
8. Gray C, Lawrence J, Schapiro J, Altman J, Winters M, Crompton M, Loi M, Kundu S, Davis M, and Merigan T: Frequency of class I HLA-restricted anti-HIV CD8+ T cells in individuals receiving highly active antiretroviral therapy (HAART). J Immunol 1999;162:1780-1788.
9. Blankson JN, Gallant JE, and Siliciano RF: Proliferative responses to human immunodeficiency virus type 1 (HIV-1) antigens in HIV-1-infected patients with immune reconstitution. J Infect Dis 2001;183:657-661.
10. + T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nat Med 1999;5:518-525.
11. Dalod M, Dupuis M, Deschemin JC, Sicard D, Salmon D, Delfraissy JF, Venet A, Sinet M, and Guillet JG: Broad, intense anti-human immunodeficiency virus (HIV) ex vivo CD8(+) responses in HIV type 1-infected patients: Comparison with anti-Epstein-Barr virus responses and changes during antiretroviral therapy. J Virol 1999;73:7108-7116.
12. Zhang Y, Huber M, Weissbrich B, Voss G, Langmann P, Klinker H, and Jassoy C: Characterization of HIV-specific proliferative T cell responses in HIV-infected persons. AIDS Res Hum Retroviruses 2001;17:623-629.
13. Rosenberg ES, Billingsley JM, Caliendo AM, Boswell SL, Sax PE, Kalams SA, and Walker BD: Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 1997;278:1447-1450.
14. Rosenberg ES, Altfeld M, Poon SH, Phillips MN, Wilkes BM, Eldridge RL, Robbins GK, D'Aquila RT, Goulder PJ, and Walker BD: Immune control of HIV-1 after early treatment of acute infection. Nature 2000;407:523-526.
15. Rinaldo CR, Jr., Liebmann JM, Huang XL, Fan Z, Al-Shboul Q, McMahon DK, Day RD, Riddler SA, and Mellors JW: Prolonged suppression of human immunodeficiency virus type 1 (HIV-1) viremia in persons with advanced disease results in enhancement of CD4 T cell reactivity to microbial antigens but not to HIV-1 antigens. J Infect Dis 1999,179:329-336.
16. Gahéry-Ségard H, Pialoux G, Charmeteau B, Sermet S, Poncelet H, Raux M, Tartar A, Lévy JP, Gras-Masse H, and Guillet JG. Multiepitopic B- and T-cell responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine. J Virol 2000;74:1694-1703.
17. Pialoux G, Gahery-Segard H, Sermet S, Poncelet H, Fournier S, Gerard L, Tartar A, Gras-Masse H, Levy JP, and Guillet JG: Lipopeptides induce cell-mediated anti-HIV immune responses in seronegative volunteers. AIDS 2001;15:1239-1249.
18. Wilson CC, Palmer B, Southwood S, Sidney J, Higashimoto Y, Appella E, Chesnut R, Sette A, and Livingston BD: Identification and antigenicity of broadly cross-reactive and conserved human immunodeficiency virus type 1-derived helper T-lymphocyte epitopes. J Virol 2001;75:4195-4207.
19. Patterson BK, McCallister S, Schutz M, Siegel JN, Shults K, Flener Z, and Landay A: Persistence of intracellular HIV-1 mRNA correlates with HIV-1-specific immune responses in infected subjects on stable HAART. AIDS 2001;15:1635-1641.
20. HIV Molecular Immunology Database http://www.hiv.lanl.gov. Los Alamos National Laboratory, Theoretical Biology and Biophysics, Los Alamos, NM, 2002.
21. Choppin J, Cohen W, Bianco A, Briand JP, Connan F, Dalod M, and Guillet JG: Characteristics of HIV-1 Nef regions containing multiple CD8+ T cell epitopes: Wealth of HLA-binding motifs and sensitivity to proteasome degradation. J Immunol 2001;166:6164-6169.
22. Betts MR, Ambrozak DR, Douek DC, Bonhoeffer S, Brenchley JM, Casazza JP, Koup RA, and Picker LJ: Analysis of total human immunodeficiency virus (HIV)-specific CD4(+) and CD8(+) T-cell responses: Relationship to viral load in untreated HIV infection. J Virol 2001;75:11983-11991.
23. Novitsky V, Cao H, Rybak N, Gilbert P, McLane MF, Gaolekwe S, Peter T, Thior I, Ndung'u T, Marlink R, Lee TH, and Essex M: Magnitude and frequency of cytotoxic T-lymphocyte responses: Identification of immunodominant regions of human immunodeficiency virus type 1 subtype C. J Virol 2002;76:10155-10168.
24. Addo MM, Yu XG, Rathod A, Cohen D, Eldridge RL, Strick D, Johnston MN, Corcoran C, Wurcel AG, Fitzpatrick CA, Feeney ME, Rodriguez WR, Basgoz N, Draenert R, Stone DR, Brander C, Goulder PJ, Rosenberg ES, Altfeld M, and Walker BD: Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J Virol 2003;77:2081-2092.
25. Kalams SA, Buchbinder SP, Rosenberg ES, Billingsley JM, Colbert DS, Jones NG, Shea AK, Trocha AK, and Walker BD: Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection. J Virol 1999;73:6715-6720.
26. + T cells in peripheral blood after initiation of highly active antiretroviral therapy. J Virol 2001;75:6508-6516.
27. Alter G, Hatzakis G, Tsoukas CM, Pelley K, Rouleau D, LeBlanc R, Baril JG, Dion H, Lefebvre E, Thomas R, Cote P, Lapointe N, Routy JP, Sekaly RP, Conway B, and Bernard NF: Longitudinal assessment of changes in HIV-specific effector activity in HIV-infected patients starting highly active antiretroviral therapy in primary infection. J Immunol 2003;171:477-488.
28. Ogg G, Jin X, Bonhoeffer S, Moss P, Nowak M, Monard S, Segal J, Cao Y, Rowland-Jones S, Hurley A, Markowitz M, Ho D, McMichael A, and Nixon D: Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy. J Virol 1999;73:797-800.
29. Appay V, Nixon DF, Donahoe SM, Gillespie GM, Dong T, King A, Ogg GS, Spiegel HM, Conlon C, Spina CA, Havlir DV, Richman DD, Waters A, Easterbrook P, McMichael AJ, and Rowland-Jones SL: HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function. J Exp Med 2000;192:63-76.
30. + T cell maturation state: Potential implications for therapeutic immunization. J Infect Dis 2003;187:364-374.
31. Andrieu M, Loing E, Desoutter JF, Connan F, Choppin J, Gras-Masse H, Hanau D, Dautry-Varsat A, Guillet JG, and Hosmalin A: Endocytosis of an HIV-derived lipopeptide into human dendritic cells followed by class I-restricted CD8(+) T lymphocyte activation. Eur J Immunol 2000;30:3256-3265.
32. Andrieu M, Desoutter JF, Loing E, Gaston J, Hanau D, Guillet JG, and Hosmalin A: Two human immunodeficiency virus vaccinal lipopeptides follow different cross-presentation pathways in human dendritic cells. J Virol 2003;77:1564-1570.